Medicine information
Uses & overview
TASMULINE DFZ is a combination pharmaceutical product marketed by Steris Healthcare, containing Tamsulosin Hydrochloride 0.4 mg PR and Deflazacort 30 mg in capsule form. Tamsulosin Hydrochloride is an alpha-1 adrenergic blocker that helps relax the smooth muscles around the prostate and bladder neck, supporting urine flow in men with urinary symptoms associated with benign prostatic hyperplasia (BPH). The PR formulation is designed for prolonged release, according to the product's approved formulation. Deflazacort is a corticosteroid that reduces inflammation by modifying the body's inflammatory and immune responses. Its use requires medical supervision because corticosteroids can cause significant adverse effects, particularly with prolonged use. The appropriate use of TASMULINE DFZ depends on its approved indication, the patient's medical condition, and the prescribing healthcare professional's assessment. The specific therapeutic indication for this combination should be confirmed from the approved product information before publication.
How to use
Take TASMULINE DFZ only as prescribed by your doctor. Follow the dosage, timing, and food instructions provided with the specific product. Do not crush, chew, or open the capsule unless the product instructions or a healthcare professional specifically confirm that this is appropriate. Do not change the dose or stop treatment without medical advice. Deflazacort may require gradual dose reduction after certain treatment regimens; abruptly stopping corticosteroid treatment can be dangerous. Inform your doctor about any other medicines you take and any history of diabetes, high blood pressure, stomach ulcers, glaucoma, liver disease, or kidney disease.
Storage
Store TASMULINE DFZ according to the conditions specified on the approved product packaging. Keep the capsules in their original packaging, away from excessive heat and moisture, and out of reach of children. Do not use the product after its expiry date.
